medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2011, Number 6

<< Back Next >>

Rev Invest Clin 2011; 63 (6)

Therapy of lysosomal storage diseases: update and perspectives

Lara-Aguilar RA, Juárez-Vázquez CI, Medina-Lozano C

Language: Spanish
References: 47
Page: 651-658
PDF size: 142.99 Kb.


ABSTRACT

Lysosomal storage diseases (LSD) are caused by monogenic mutations in genes coding for multiple aberrant proteins involved in the catabolism of complex lipids, glycosaminoglycans, oligosaccharides, or nucleic acids. The pathophysiology of the LSD is due to abnormal accumulation of non-hydrolyzed substrate in the lysosomes, affecting the architecture and function of cells, tissues and organs. Due to their genic and allelic heterogeneity, the LSD present a wide clinical spectrum in severity of symptoms, evolution and age of onset. The therapeutic strategy has two goals: 1) Palliative management of symptoms (splenectomy, surgery to improve or restore joints or bones, drugs for CNS symptoms, etc.), and 2) The correction of activity of the mutant protein, the former has two approaches: A) Replacing deficient protein (bone marrow transplantation, hematopoietic stem cells or umbilical cord blood cells; replacement with recombinant enzyme and gene therapy) and B) Activate or enhanced the functionality of the mutant enzyme with therapeutic small molecules. Neither of the known treatments is able to address all aspects of these multisystemic disorders, nor cure the patients. Currently, the combination of corrective therapy (CT) with paliative therapy (PT) is the most promising strategy to solve most of the multisystem manifestations. The multidisciplinary medical care is fundamental for diagnosis, treatment and control of disease. Nanotechnology opens a promising new era in the treatment of LSD. Finally, the LSD that has CT must be included in newborn screening programs in order to implement timely treatment and prevent irreversible damage.


REFERENCES

  1. Aerts JM, van Breemen MJ, Bussink AP, Brinkman J, Hollak CEM, Langeveld M, et al. The blood–brain barrier and treatment of lysosomal storage diseases. International Congress Series 2005; 1277: 19-31.

  2. Macauley SL, Sands M. Promising CNS-directed enzyme replacement therapy for lysosomal storage diseases. Exp Neurol 2009; 218(1): 5-8.

  3. Volkmar G. Cellular pathophysiology of lysosomal storage diseases. Chapter 4. In: Mehta A, Beck M, Sunder-Plassmann G (eds.). Fabry Disease. Perspectives from 5 Years of FOS. Oxford PharmaGenesis; 2006.

  4. Staretz-Chacham O, Lang TC, LaMarca ME, Krasnewich D, Sidransky E. Lysosomal storage disorders in the newborn. Pediatrics 2009; 123: 1191.

  5. Fuller M, Meikle PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. Chapter 2. In: Mehta A, Beck M, Sunder-Plassmann G (eds.). Fabry disease: Perspectives from 5 years of FOS. Oxford PharmaGenesis 2006.

  6. Poupetová H, Ledvinová J, Berná L, Dvoráková L, Kozich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. J Inherit Metab Dis 2010; 33(4): 387-96.

  7. Moammar H, Cheriyan G, Mathew R, Al-Sannaa N. Incidence and patterns of inborn errors of metabolism in the Eastern Province of Saudi Arabia, 1983-2008. Ann Saudi Med 2010; 30(4): 271-7.

  8. Spada M, Pagliardini S, Yasuda M, Tukel T, Thiagarajan G, Sakuraba H, et al. High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79(1): 31-40.

  9. Haskins M. Gene therapy for lysosomal storage diseases (LSDs) in large animal models. ILAR J 2009; 50(2): 112-21.

  10. Consenso Mexicano de diagnóstico, tratamiento y seguimiento. Enfermedades por depósito lisosomal. Gac Med Mex 2008; 144(Supl. 1): 1-24.

  11. Futerman AH, Van Meer G. The cell biology of lysosomal storage disorders. Nature Reviews. Mol Cell Biol 2004; 5: 554-65.

  12. Pastores GM, Derralynn AH. Gaucher disease. Gene reviews [Internet]. Pagon RA, Bird TC, Dolan CR, Stephens K (eds.). Seattle (WA): University of Washington [Last update: March 13, 2008].

  13. Freeze HH. Genetic disorders of glycan degradation. Chapter 41. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR (eds.). Essentials of glycobiology. 2nd Ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2009.

  14. Hoogerbrugge PM, Valerio D. Bone marrow transplantation and gene therapy for lysosomal storage diseases. Bone Marrow Transp 1998; Suppl 2: S34-S36.

  15. Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010; 62(1): 33-40.

  16. Prasad VK, Kurtzberg J. Cord blood and bone marrow transplantation in inherited metabolic diseases: scientific basis, current status and future directions. Br J Haematol 2010; 148(3): 356-72.

  17. Beutler E. Enzyme replacement in Gaucher disease. PLoS Med 2004; 1(2): e21.

  18. Goker-Alpan O. Optimal therapy in Gaucher disease. Therap and Clin Risk Manag 2010; 6: 315-23.

  19. Parenti G. Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Mol Med 2009; 1(5): 268-79.

  20. Platt FM, Jeyakumar M. Substrate reduction therapy. Act Paediatr 2008; Suppl. 97(457): 88-93.

  21. Carraresi L, Parini R, Filoni C, Caciotti A, Sersale G, Tomatsu S, et al. GALNS gene expression profiling in Morquio A patients’ fibroblasts. Clin Chim Act 2008; 397(1-2): 72-6.

  22. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, Chen F, et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 2009; 52(9): 2836-45.

  23. Gagliardi C, Bunnell BA. Large animal models of neurological disorders for gene therapy. ILAR J 2009; 50(2): 128-43.

  24. McIntyre C, Byers S, Anson DS. Correction of mucopolysaccharidosis type IIIA somatic and central nervous system pathology by lentiviral-mediated gene transfer. J Gene Med 2010; 12(9): 717-28.

  25. Shihabuddin LS, Aubert I. Stem cell transplantation for neurometabolic and neurodegenerative diseases. Neuropharm 2010; 58(6): 845-54.

  26. Heldermon CD, Ohlemiller KK, Herzog ED, Vogler C, Qin E, Wozniak DF, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Therap 2010; 18(5): 873-80.

  27. Douillard-Guilloux G, Richard E, Batista L, Caillaud C. Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of alpha-glucosidase in Pompe disease. J Gene Med 2009; 11(4): 279-87.

  28. Heldermon CD, Ohlemiller KK, Herzog ED, Vogler C, Qin E, Wozniak DF, et al. Therapeutic efficacy of bone marrow transplant, intracranial AAV-mediated gene therapy, or both in the mouse model of MPS IIIB. Mol Ther 2010; 18(5): 873-80.

  29. Online Mendelian Inheritance in Man, OMIM. Available from: http://www.ncbi.nlm.nih.gov/omim [Consultado: junio 2011].

  30. ClinicalTrials.gov. A service of the US National Institutes of Health. Available from: http://www.clinicaltrials.gov/ct2/home [Consultado: junio 2011].

  31. Luan Z, Higaki K, Aguilar Moncayo M, et al. Chaperone activity of Bicyclic Nojirimicyn analogues for gaucher mutations in comparison with N(N-nonil) Deoxynojirimycin. Chem Biochem 2009; 10(17): 2780-92.

  32. Connock M, Juarez-Garcia A, Frew E, Mans A, Dretzke J, Fry- Smith A, Moore D. A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1. Health Tech Asses 2006; 10(20): Feedback.

  33. Fluharty AL. Arylsulfatase A deficiency. Metachromatic leukodystrophy. GeneReviews [Internet]. Pagon RA, Bird TC, Dolan CR, Stephens K (eds.). Seattle (WA): University of Washington, Seattle. Last Updated: September 23, 2008.

  34. Wenger DA. Krabbe Disease. Gene Reviews [Internet]. Pagon RA, Bird TC, Dolan CR, Stephens K [eds.]. Seattle (WA): University of Washington [Last update: August 5, 2008].

  35. Kaback MM. Hexosaminidase A deficiency. Tay-Sachs Disease. Gene Reviews [Internet]. Pagon RA, Bird TC, Dolan CR, Stephens K (eds.). Seattle (WA): University of Washington [Last updated: May 19, 2006].

  36. Tallaksen CM, Berg JE. Miglustat therapy in juvenile Sandhoff disease. J Inherit Metab Dis 2009 [Epub ahead of print].

  37. Beck M. Emerging drugs for lysosomal storage diseases. Expert Opin Emerg Drugs 2010; 15(3): 495-507.

  38. Martin RA. Mucopolysaccharidosis type II. Hunter syndrome. Gene Reviews [Internet]. Pagon RA, Bird TC, Dolan CR, Stephens K (ed.). Seattle (WA): University of Washington [Last Update: November 6, 2007]

  39. Arfi A, Richard M, Gandolphe C, Scherman D. Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J Inherit Metab Dis 2010; 33(1): 61-7.

  40. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr 2004; 144(Suppl. 5): 35-43.

  41. Pattersona MC, Platt F. Therapy of Niemann–Pick disease type C. Biochim Biophys Act 2004; 1685: 77-82.

  42. Leroy JG, Cathey S, Friez MJ. Mucolipidosis II. I-Cell Disease. Gene Reviews [Internet]. Pagon RA, Bird TC, Dolan CR, Stephens K (eds.). Seattle (WA): University of Washington [Last Revision: July 7, 2009].

  43. Marsden D, Levy H. Newborn screening of lysosomal storage disorders. Clin Chem 2010; 56(7): 1071-9.

  44. Hwu WL, Chien YH, Lee NC. Newborn screening for neuropathic lisosomal storage disorders. J Inherit Metab Dis 2010; 33(4): 381-6.

  45. Nakamura K, Hattori K, Endo F. Newborn screening for lisosomal storage disorders. Am J Med Genet C Semin Med Genet 2011; 157(1): 63-71.

  46. Bareford LM, Swaan PW. Endocytic mechanism for targeted drug delivery. Adv Drug Deliv Rev 2007; 59(8): 748-58.

  47. Bhaskar S, Tian F, Stoeger T, Kreyling W, de la Fuente JM, Grazú V, et al. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part and Fib Toxicol 2010; 7: 3-27.




2020     |     www.medigraphic.com